Chemistry:Radotinib
 | |
| Clinical data | |
|---|---|
| Trade names | Supect |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C27H21F3N8O |
| Molar mass | 530.515 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Radotinib (INN; trade name Supect), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)[1] with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
Radotinib is being developed by Ilyang Pharmaceutical Co., Ltd of South Korea[2] and is co-marketed by Daewoong Pharmaceutical Co. Ltd, in South Korea.[3] Radotinib completed a multi-national Phase II clinical trial study in 2012[4] and in August 2011, Ilyang initiated a Phase III, multinational, multi-center, open-label, randomized study for first-line indication.[5] Its mechanism of action involves inhibition of the Bcr-Abl tyrosine kinase and of platelet-derived growth factor receptor (PDGFR).[6]
References
- ↑ "To Market, To Market - 2012: Radotinib (Anticancer)". Annual Reports in Medicinal Chemistry 48: 523–524. 2013. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 9780124171503.
- ↑ "Il-Yang Pharmaceutical". http://www.ilyang.co.kr/english/rnd/rnd03.asp.
- ↑ "Daewoong will market Ilyang's new leukemia drug". Daily Pharm News. 23 October 2012. http://www.dailypharm.com/Users/News/EnglishNews.html?NewsID=3108&nStart=1023&mode=&searchValue=.
- ↑ "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors". Haematologica 99 (7): 1191–1196. July 2014. doi:10.3324/haematol.2013.096776. PMID 24705186.
- ↑ Clinical trial number NCT01511289 for "A Phase 3 Multinational, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Ph+ CML Patients in Early Chronic Phase" at ClinicalTrials.gov
- ↑ "Radotinib hydrochloride". NCI Drug Dictionary. National Cancer Institute. 2011-02-02. http://www.cancer.gov/drugdictionary?cdrid=723999.
 |  |
